154 results on '"David S. Rosenthal"'
Search Results
2. Factitiously Elevated Total Triiodothyronine in a Euthyroid Patient with Multiple Myeloma
- Author
-
Kaushik Mandal, Damilola Ashorobi, Alice Lee, Huijuan Liao, Salini C. Kumar, and David S. Rosenthal
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Sporadic reports of factitious elevations of thyroid hormones related to laboratory interference from autoantibodies and multiple myeloma paraproteins have appeared in the literature. Such clinically confusing laboratory results can lead to erroneous diagnoses and inappropriate treatments. We report an additional case of a patient with multiple myeloma and an IgG paraproteinemia who had such a spurious elevation of total T3 complicating her levothyroxine management of hypothyroidism. In addition, we alert clinicians that differences in performance characteristics between various manufacturers’ test platforms may also cause spurious reports.
- Published
- 2021
- Full Text
- View/download PDF
3. Ectopic Parathyroid Hormone Secretion by A Penile Squamous Cell Carcinoma
- Author
-
Zahily Sardiñas, MD, Shayhira Suazo, MD, Salini Kumar, MD, Alice Lee, MD, and David S. Rosenthal, MD
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
ABSTRACT: Objective: Ectopic paraneoplastic secretion of parathyroid hormone (PTH) is rare, with only 25 cases previously reported in the literature, including only 2 attributed to squamous cell carcinoma. The recent presentation of such a patient and subsequent review of the literature has alerted us to the need for clinicians to consider such an etiology in patients presenting with humeral hypercalcemia of malignancy.Methods: Significant hypercalcemia occurred in a 48-year-old male with metastatic squamous cell carcinoma of the penis. The patient had hypercalcemia, elevated PTH, and normal PTH-related protein (PTHrp), without evidence of tumoral skeletal involvement. Comorbid primary hyperparathyroidism was suspected, but ultrasound and sestamibi scans of the neck were negative, raising the possibility of ectopic PTH production. This was confirmed by computed tomography–guided needle biopsy of a thigh metastatic lesion showing positive histochemical staining for PTH-specific antibodies and markedly elevated PTH levels in the aspirated lesion fluid.Results: Paraneoplastic ectopic PTH production is well documented but rare. This is only the third such case to be reported due to squamous cell carcinoma and the first associated with a penile primary neoplasm. Diagnosis in our patient required exclusion of neoplastic lytic bone lesions, tumoral secretion of PTHrp, or comorbid primary hyperparathyroidism, as well as positive histochemical staining of tumor cells obtained at biopsy for PTH and very high levels of PTH from fluid aspirated from a metastasis. In spite of aggressive chemotherapy and management of hypercalcemia, the patient did not survive.Conclusion: Ectopic paraneoplastic PTH secretion is rare, but clinicians need to be alert to its possibility and aggressively seek out the diagnosis. Unfortunately, management is difficult, and even with aggressive treatment, survival is poor.Abbreviations: CT computed tomography; HHM humeral hypercalcemia of malignancy; PTH parathyroid hormone; PTHrp parathyroid hormone–related protein
- Published
- 2018
- Full Text
- View/download PDF
4. Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care
- Author
-
Yair Maimon PhD, Noah Samuels MD, Zoya Cohen PhD, Raanan Berger MD, PhD, and David S. Rosenthal MD
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and Purpose: LCS101 is a botanical formula extracted from 14 botanical components. While conventional oncology focuses on targeted medicine, research on LCS101 adopts a multi-targeted approach, examining its preclinical (in vitro, in vivo, and ex vivo) and clinical (randomized controlled trial, pragmatic) effects. This includes examining the formula’s impact on the immune system, selective anticancer effects, and improved chemotherapy-related symptoms and quality of life. Effects on the Immune System: In murine splenic cell cultures, LCS101 significantly increased T-cell proliferation and macrophage tumor necrosis factor-α production. Blood samples from healthy volunteers exposed to LCS101 showed a dose-dependent increase in natural killer cell activity; and a randomized controlled trial showed significantly lower rates of leucopenia/neutropenia and anemia in patients with breast cancer undergoing chemotherapy. Selective Anticancer Effects: In vitro LCS101 demonstrated selective growth inhibition (on XTT viability assay) in human breast and prostate cancer cell lines, without any harmful effects on normal human epithelial cells. The anticancer effects were attributed to reactive oxygen species activity. Cytotoxic effects of doxorubicin and 5-fluorouracil on breast cancer cell lines were significantly increased following exposure to LCS101, with a protective effect in normal cells. Symptom Relief and Quality of Life: Clinical research shows that patients taking LCS101 during chemotherapy are less likely to report symptoms such as fatigue, pain, nausea and vomiting. Conclusion: LCS101 exhibits multi-targeted effects, with significant implications for cancer care. Further research is needed to better understand the impact of these findings.
- Published
- 2018
- Full Text
- View/download PDF
5. Prolonged Progression-Free Survival with Partial Disease Regression in Advanced Metastatic Medullary Thyroid Carcinoma Treated with Vandetanib
- Author
-
Sravanthi Sanivarapu, MD, Zahily Sardiñas, MD, Salini C. Kumar, MD, David S. Rosenthal, MD, Wondwossen Gebre, MD, and Minakshi Ramchand, MD
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
ABSTRACT: Objective: Medullary thyroid cancer (MTC), derived from thyroidal parafollicular C-cells, is a difficult treatment problem when presenting with advanced and meta-static disease. The recent addition of targeted systemic medical therapy with tyrosine kinase inhibitors has shown great promise for disease control and prolonged survival for these patients. We present a case of a young woman with such advanced disease who has had a significant and prolonged response to treatment with the tyrosine kinase inhibitor vandetanib. We wish to alert clinicians to the use of such therapy in appropriate cases.Methods: A 22-year-old woman was referred to our medical center with MTC. Having already undergone total thyroidectomy followed by external beam radiotherapy of involved left neck lymph nodes, she presented to our institution with a significant paratracheal tumor burden and extensive pulmonary metastases. She was given systemic tyrosine kinase inhibitor treatment with vandetanib.Results: The patient, suffering no significant adverse effects of therapy, has responded biochemically showing durable reductions in calcitonin, carcinoembryonic antigen, and chromogranin A, and she has had progression-free survival with a documented partial response and disease regression after 39 months of continuous therapy.Conclusion: Advanced and metastatic MTC has classically had a poor prognosis. However, the recent introduction of systemic tyrosine kinase inhibitor therapy has greatly improved the outlook for these patients. Clinicians should be alert to this advance in therapeutics for use in selected appropriate patients.Abbreviations: CEA = carcinoembryonic antigen;CT = computed tomography;MTC = medullary thyroid cancer;PFS = progression-free survival;PR = partial response;RET = RE-arranged during Transfection;SD = stable disease;VEGFR = vascular endothelial growth factor receptor
- Published
- 2018
- Full Text
- View/download PDF
6. LBODP097 Malignant Struma Ovarii: Long Term Successful Treatment. Outcome
- Author
-
Kaushik Mandal, Huijuan Liao, Damilola Ashorobi, Salini Chellappan Kumar, and David S Rosenthal
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
18 year old African American female saw her GYN in 9/2008 for abdominal pain. CT: bilateral adnexal masses (10×8 cm left; 6.3×3.1 cm right). Surgical pathology reported a left benign cystic teratoma and right corpus luteum cyst. Pain recurred in 2010. MRI showed: 9×7.5×4 cm right adnexal mass. Repeat surgery was done. Pathology: benign cystic teratoma with focal thyroid tissue - "Struma Ovarii". Abdominal pain recurred yet again in 2012. Sonography revealed a mixed solid/cystic pelvic mass measuring 10.6×7.9×7.6 cm. Exploratory laparotomy 9/2012 revealed a right adnexal mass and widespread peritoneal nodules. Pathology reported follicular tissue with colloid in the nodules - "Peritoneal Strumatosis" suggesting benignity. Upon further review was reclassified as metastatic well differentiated follicular thyroid cancer of ovarian origin with follicular thyroid tissue identified in peritoneal lymph nodes, spleen, bladder and rectal wall. The patient was then referred to endocrinology at our facility. On exam she was clinically euthyroid without thyromegaly or nodularity. Thyroid hormone levels were normal. Antithyroid antibodies were absent. Serum Thyroglobulin (Tg): elevated (229; normal 2-35 ng/ml) as was CA125 (64; normal 110. 0 uIU/ml. Presentation: No date and time listed
- Published
- 2022
- Full Text
- View/download PDF
7. Factitiously Elevated Total Triiodothyronine in a Euthyroid Patient with Multiple Myeloma
- Author
-
Salini Chellappan Kumar, Kaushik Mandal, Damilola Ashorobi, David S. Rosenthal, Huijuan Liao, and Alice Lee
- Subjects
Paraproteinemia ,Pediatrics ,medicine.medical_specialty ,Triiodothyronine ,business.industry ,Endocrinology, Diabetes and Metabolism ,Autoantibody ,Levothyroxine ,Case Report ,medicine.disease ,RC648-665 ,Diseases of the endocrine glands. Clinical endocrinology ,Thyroid hormones ,Medicine ,Euthyroid ,Paraproteins ,business ,Multiple myeloma ,medicine.drug - Abstract
Sporadic reports of factitious elevations of thyroid hormones related to laboratory interference from autoantibodies and multiple myeloma paraproteins have appeared in the literature. Such clinically confusing laboratory results can lead to erroneous diagnoses and inappropriate treatments. We report an additional case of a patient with multiple myeloma and an IgG paraproteinemia who had such a spurious elevation of total T3 complicating her levothyroxine management of hypothyroidism. In addition, we alert clinicians that differences in performance characteristics between various manufacturers’ test platforms may also cause spurious reports.
- Published
- 2021
8. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial
- Author
-
Rachel A. Freedman, Anita Giobbie-Hurder, Nan Lin, Im Hee Shin, Weidong Lu, Ann H. Partridge, David S. Rosenthal, and Jennifer A. Ligibel
- Subjects
Cancer Research ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Cancer ,medicine.disease ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Peripheral neuropathy ,Breast cancer ,Oncology ,Chemotherapy-induced peripheral neuropathy ,030220 oncology & carcinogenesis ,Internal medicine ,Neuropathic pain ,Acupuncture ,medicine ,business ,education ,030217 neurology & neurosurgery - Abstract
Background Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating long-term side effects in breast cancer survivors. We conducted a randomized controlled pilot trial to assess the feasibility, safety, and effects of an acupuncture intervention on CIPN in this population. Patients and methods Women with stage I-III breast cancer with grade 1 or higher CIPN after taxane-containing adjuvant chemotherapy were randomized 1:1 to an immediate acupuncture (IA) arm or to a waitlist control group (CG). Participants in the IA arm received 18 sessions of acupuncture over 8 weeks, then received no additional acupuncture. Patients in the CG arm received usual care over 8 weeks, followed by nine sessions of acupuncture over 8 weeks. Measures including Patient Neurotoxicity Questionnaire (PNQ), Functional Assessment of Cancer Therapy-Neurotoxicity subscale (FACT-NTX), and Brief Pain Inventory-short form (BPI-SF) were collected at baseline and at 4, 8, and 16 weeks after enrollment. Results Forty women (median age, 54) were enrolled (20 to IA and 20 to CG), with median time between completion of chemotherapy and enrollment of 14 months (range 1-92). At 8 weeks, participants in the IA arm experienced significant improvements in PNQ sensory score (-1.0 ± 0.9 vs. -0.3 ± 0.6; p = .01), FACT-NTX summary score (8.7 ± 8.9 vs. 1.2 ± 5.4; p = .002), and BPI-SF pain severity score (-1.1 ± 1.7 vs. 0.3 ± 1.5; p = .03), compared with those in the CG arm. No serious side effects were observed. Conclusion Women with CIPN after adjuvant taxane therapy for breast cancer experienced significant improvements in neuropathic symptoms from an 8-week acupuncture treatment regimen. Additional larger studies are needed to confirm these findings. Implications for practice Chemotherapy-induced peripheral neuropathy (CIPN) is a toxicity that often persists for months to years after the completion of adjuvant chemotherapy for early breast cancer. In a randomized pilot trial of 40 breast cancer survivors with CIPN, an 8-week acupuncture intervention (vs. usual care) led to a statistically and clinically significant improvement in subjective sensory symptoms including neuropathic pain and paresthesia. Given the lack of effective therapies and established safety profile of acupuncture, clinicians may consider acupuncture as a treatment option for mild to moderate CIPN in practice.
- Published
- 2019
- Full Text
- View/download PDF
9. The Effects of Tai Chi and Qigong on Immune Responses: A Systematic Review and Meta-Analysis
- Author
-
Lidia Schapira, Kyeore Bae, Gillian Lamoury, Byeongsang Oh, Stephen Clarke, David S. Rosenthal, Thomas Eade, Frances M. Boyle, Albert Yeung, Michael Back, and Brian Corless
- Subjects
medicine.medical_specialty ,Psychological intervention ,MEDLINE ,lcsh:Medicine ,Inflammation ,Review ,Systemic inflammation ,Tai Chi ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Randomized controlled trial ,law ,Internal medicine ,medicine ,General Environmental Science ,qigong ,business.industry ,lcsh:R ,General Engineering ,COVID-19 ,immunity ,Coronavirus ,immune system ,inflammation ,030220 oncology & carcinogenesis ,Meta-analysis ,General Earth and Planetary Sciences ,Biomarker (medicine) ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Background: Effective preventative health interventions are essential to maintain well-being among healthcare professionals and the public, especially during times of health crises. Several studies have suggested that Tai Chi and Qigong (TQ) have positive impacts on the immune system and its response to inflammation. The aim of this review is to evaluate the current evidence of the effects of TQ on these parameters. Methods: Electronic searches were conducted on databases (Medline, PubMed, Embase and ScienceDirect). Searches were performed using the following keywords: “Tai Chi or Qigong” and “immune system, immune function, immunity, Immun*, inflammation and cytokines”. Studies published as full-text randomized controlled trials (RCTs) in English were included. Estimates of change in the levels of immune cells and inflammatory biomarkers were pooled using a random-effects meta-analysis where randomised comparisons were available for TQ versus active controls and TQ versus non-active controls. Results: Nineteen RCTs were selected for review with a total of 1686 participants and a range of 32 to 252 participants within the studies. Overall, a random-effects meta-analysis found that, compared with control conditions, TQ has a significant small effect of increasing the levels of immune cells (SMD, 0.28; 95% CI, 0.13 to 0.43, p = 0.00), I2 = 45%, but not a significant effect on reducing the levels of inflammation (SMD, −0.15; 95% CI, −0.39 to 0.09, p = 0.21), I2 = 85%, as measured by the systemic inflammation biomarker C-reactive protein (CRP) and cell mediated biomarker cytokines. This difference in results is due to the bidirectional regulation of cytokines. An overall risk of bias assessment found three RCTs with a low risk of bias, six RCTs with some concerns of bias, and ten RCTs with a high risk of bias. Conclusions: Current evidence indicates that practising TQ has a physiologic impact on immune system functioning and inflammatory responses. Rigorous studies are needed to guide clinical guidelines and harness the power of TQ to promote health and wellbeing.
- Published
- 2020
10. Botanical Formula LCS101: A Multi-Targeted Approach to Cancer Care
- Author
-
Noah Samuels, David S. Rosenthal, Zoya Cohen, Raanan Berger, and Yair Maimon
- Subjects
0301 basic medicine ,Oncology ,safety ,Male ,medicine.medical_specialty ,multi-targeted ,Antineoplastic Agents ,Breast Neoplasms ,anticancer ,botanical compound ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Internal medicine ,Commentaries ,Cell Line, Tumor ,medicine ,selective ,Animals ,Humans ,RC254-282 ,Cell Proliferation ,Randomized Controlled Trials as Topic ,LCS101 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,Prostatic Neoplasms ,medicine.disease ,HCT116 Cells ,Killer Cells, Natural ,immune system ,030104 developmental biology ,RAW 264.7 Cells ,Complementary and alternative medicine ,030220 oncology & carcinogenesis ,MCF-7 Cells ,Quality of Life ,Female ,business ,protective ,Reactive Oxygen Species ,Drugs, Chinese Herbal - Abstract
Background and Purpose: LCS101 is a botanical formula extracted from 14 botanical components. While conventional oncology focuses on targeted medicine, research on LCS101 adopts a multi-targeted approach, examining its preclinical (in vitro, in vivo, and ex vivo) and clinical (randomized controlled trial, pragmatic) effects. This includes examining the formula’s impact on the immune system, selective anticancer effects, and improved chemotherapy-related symptoms and quality of life. Effects on the Immune System: In murine splenic cell cultures, LCS101 significantly increased T-cell proliferation and macrophage tumor necrosis factor-α production. Blood samples from healthy volunteers exposed to LCS101 showed a dose-dependent increase in natural killer cell activity; and a randomized controlled trial showed significantly lower rates of leucopenia/neutropenia and anemia in patients with breast cancer undergoing chemotherapy. Selective Anticancer Effects: In vitro LCS101 demonstrated selective growth inhibition (on XTT viability assay) in human breast and prostate cancer cell lines, without any harmful effects on normal human epithelial cells. The anticancer effects were attributed to reactive oxygen species activity. Cytotoxic effects of doxorubicin and 5-fluorouracil on breast cancer cell lines were significantly increased following exposure to LCS101, with a protective effect in normal cells. Symptom Relief and Quality of Life: Clinical research shows that patients taking LCS101 during chemotherapy are less likely to report symptoms such as fatigue, pain, nausea and vomiting. Conclusion: LCS101 exhibits multi-targeted effects, with significant implications for cancer care. Further research is needed to better understand the impact of these findings.
- Published
- 2018
11. Prolonged Progression-Free Survival with Partial Disease Regression in Advanced Metastatic Medullary Thyroid Carcinoma Treated with Vandetanib
- Author
-
David S. Rosenthal, Sravanthi Sanivarapu, Zahily Sardiñas, Wondwossen Gebre, Minakshi Ramchand, and Salini Chellappan Kumar
- Subjects
Oncology ,endocrine system ,medicine.medical_specialty ,endocrine system diseases ,Medullary cavity ,business.industry ,Medullary thyroid cancer ,030209 endocrinology & metabolism ,General Medicine ,Disease ,RC648-665 ,medicine.disease ,Vandetanib ,Diseases of the endocrine glands. Clinical endocrinology ,Thyroid carcinoma ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,Progression-free survival ,business ,Disease regression ,medicine.drug - Abstract
Objective: Medullary thyroid cancer (MTC), derived from thyroidal parafollicular C-cells, is a difficult treatment problem when presenting with advanced and meta-static disease. The recent addition of targeted systemic medical therapy with tyrosine kinase inhibitors has shown great promise for disease control and prolonged survival for these patients. We present a case of a young woman with such advanced disease who has had a significant and prolonged response to treatment with the tyrosine kinase inhibitor vandetanib. We wish to alert clinicians to the use of such therapy in appropriate cases.Methods: A 22-year-old woman was referred to our medical center with MTC. Having already undergone total thyroidectomy followed by external beam radiotherapy of involved left neck lymph nodes, she presented to our institution with a significant paratracheal tumor burden and extensive pulmonary metastases. She was given systemic tyrosine kinase inhibitor treatment with vandetanib.Results: The patient, suffering no significant adverse effects of therapy, has responded biochemically showing durable reductions in calcitonin, carcinoembryonic antigen, and chromogranin A, and she has had progression-free survival with a documented partial response and disease regression after 39 months of continuous therapy.Conclusion: Advanced and metastatic MTC has classically had a poor prognosis. However, the recent introduction of systemic tyrosine kinase inhibitor therapy has greatly improved the outlook for these patients. Clinicians should be alert to this advance in therapeutics for use in selected appropriate patients.Abbreviations: CEA = carcinoembryonic antigen;CT = computed tomography;MTC = medullary thyroid cancer;PFS = progression-free survival;PR = partial response;RET = RE-arranged during Transfection;SD = stable disease;VEGFR = vascular endothelial growth factor receptor
- Published
- 2018
- Full Text
- View/download PDF
12. Oncology Acupuncture for Chronic Pain in Cancer Survivors
- Author
-
Weidong Lu and David S. Rosenthal
- Subjects
Oncology ,Clinical Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Chronic pain ,Cancer ,Neck dissection ,Hematology ,Guideline ,medicine.disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Peripheral neuropathy ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,Internal medicine ,Acupuncture ,medicine ,030212 general & internal medicine ,business - Abstract
Chronic pain syndromes associated with cancer treatment are common but difficult to manage. The American Society of Clinical Oncology recently published a practice guideline to address the unmet needs of cancer survivors, Management of Chronic Pain in Survivors of Adult Cancers, which stresses the importance of implementing integrative therapies including acupuncture. This review focuses on randomized clinical trials of acupuncture for chronic pain in cancer survivors, including its use in chemotherapy-induced peripheral neuropathy, aromatase inhibitor-associated arthralgia, and post neck dissection pain, and provides future directions of oncology acupuncture research in cancer survivorship. The features of oncology acupuncture are also discussed.
- Published
- 2018
- Full Text
- View/download PDF
13. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
- Author
-
George Hruby, Thomas Eade, Byeongsang Oh, Gillian Lamoury, Susan Carroll, Frances M. Boyle, Wen Liu, Mark Stevens, Towia A. Libermann, Nick Pavlakis, David S. Rosenthal, Andrew Kneebone, Mark P. Molloy, Benjamin Kong, Stephen Clarke, Michael Back, Brian Corless, and Marita Morgia
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,gut microbiome ,immune checkpoint inhibitor ,Review ,Disease ,Gut flora ,Cancer immunotherapy ,Renal cell carcinoma ,Internal medicine ,Carcinoma ,cancer ,Medicine ,Microbiome ,RC254-282 ,biology ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,Immunotherapy ,biology.organism_classification ,medicine.disease ,immunotherapy ,business - Abstract
Simple Summary The current review assessed the effects of the gut microbiome on clinical outcomes of immunotherapy and related adverse events (AEs) in cancer patients. Studies (n = 10) consistently reported that the gut microbiome prior to administering immune checkpoint inhibitors (ICIs) was associated with enhanced efficacy of ICIs and reduced AEs. Recent fecal microbiome transplant (FMT) studies demonstrated the modulatory effects of FMT on the composition and diversity of the gut microbiome in patients with refractory cancers and the potential to improve the efficacy of ICIs. Abstract Background: Emerging evidence suggests that gut microbiota influences the clinical response to immunotherapy. This review of clinical studies examines the relationship between gut microbiota and immunotherapy outcomes. Method: A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “immunotherapy/immune checkpoint inhibitor” and “microbiome/microbiota” and/or “fecal microbiome transplant FMT”. The relevant literature was selected for this article. Results: Ten studies examined patients diagnosed with advanced metastatic melanoma (n = 6), hepatocellular carcinoma (HCC) (n = 2), non-small cell lung carcinoma (NSCLC) (n = 1) and one study examined combination both NSCLC and renal cell carcinoma (RCC) (n = 1). These studies consistently reported that the gut microbiome profile prior to administering immune checkpoint inhibitors (ICIs) was related to clinical response as measured by progression-free survival (PFS) and overall survival (OS). Two studies reported that a low abundance of Bacteroidetes was associated with colitis. Two studies showed that patients with anti-PD-1 refractory metastatic melanoma experienced improved response rates and no added toxicity when receiving fecal microbiota transplant (FMT) from patients with anti-PD-1 responsive disease. Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted.
- Published
- 2021
- Full Text
- View/download PDF
14. Health and well-being benefits of spending time in forests: systematic review
- Author
-
Albert Yeung, David S. Rosenthal, Linda Larkey, Byeongsang Oh, Michael Back, Chris Zaslawski, and Kyung Ju Lee
- Subjects
Gerontology ,medicine.medical_specialty ,MEDLINE ,Review Article ,Forests ,010501 environmental sciences ,Toxicology ,01 natural sciences ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Environmental health ,medicine ,Humans ,Green environment ,030212 general & internal medicine ,Forest ,Health policy ,Randomized Controlled Trials as Topic ,0105 earth and related environmental sciences ,business.industry ,Wellbeing ,Public health ,lcsh:Public aspects of medicine ,Public Health, Environmental and Occupational Health ,lcsh:RA1-1270 ,General Medicine ,Nature ,Health promotion ,Health ,Well-being ,Quality of Life ,Anxiety ,Health education ,medicine.symptom ,business ,Stress, Psychological - Abstract
© The Author(s) 2017. Background: Numerous studies have reported that spending time in nature is associated with the improvement of various health outcomes and well-being. This review evaluated the physical and psychological benefits of a specific type of exposure to nature, forest therapy. Method: A literature search was carried out using MEDLINE, PubMed, ScienceDirect, EMBASE, and ProQuest databases and manual searches from inception up to December 2016. Key words: "Forest" or "Shinrin -Yoku" or "Forest bath" AND "Health" or "Wellbeing". The methodological quality of each randomized controlled trials (RCTs) was assessed according to the Cochrane risk of bias (ROB) tool. Results: Six RCTs met the inclusion criteria. Participants' ages ranged from 20 to 79 years. Sample size ranged from 18 to 99. Populations studied varied from young healthy university students to elderly people with chronic disease. Studies reported the positive impact of forest therapy on hypertension (n = 2), cardiac and pulmonary function (n = 1), immune function (n = 2), inflammation (n= 3), oxidative stress (n = 1), stress (n = 1), stress hormone (n= 1), anxiety (n= 1), depression (n = 2), and emotional response (n = 3). The quality of all studies included in this review had a high ROB. Conclusion: Forest therapy may play an important role in health promotion and disease prevention. However, the lack of high-quality studies limits the strength of results, rendering the evidence insufficient to establish clinical practice guidelines for its use. More robust RCTs are warranted.
- Published
- 2017
- Full Text
- View/download PDF
15. The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review
- Author
-
Byeongsang Oh, Marita Morgia, Susan Carroll, Gillian Lamoury, Mark Stevens, Frances M. Boyle, Michael Back, Brian Corless, Andrew Kneebone, David S. Rosenthal, Stephen Clarke, Mark P. Molloy, George Hruby, and Thomas Eade
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,gut microbiome ,Review ,Gastroenterology ,chemoradiotherapy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,medicine ,cancer ,Microbiome ,gastrointestinal toxicities ,Prospective cohort study ,Adverse effect ,RC254-282 ,radiotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Cancer ,medicine.disease ,Radiation therapy ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,business ,Dysbiosis ,Chemoradiotherapy - Abstract
Simple Summary A substantial proportion of cancer patients receive radiotherapy (RT) during their cancer trajectory. One of the most challenging pelvic RT-related toxicities are gastrointestinal (GI) toxicities (e.g., abdominal pain, rectal bleeding, faecal incontinence, and diarrhoea) which impair the quality of life (QoL) of patients. Mounting evidence suggests that gut microbiota plays a pivotal role in health and disease, including cancer. Our current clinical review aims to assess the impact of RT on gut microbiota and GI toxicities in cancer patients to provide useful information, in addition to standard care, for clinicians and patients. Abstract Background: Gastrointestinal (GI) toxicities are common adverse effects of pelvic radiotherapy (RT). Several recent studies revealed that toxicity of RT is associated with dysbiosis of the gut microbiome. Method: A literature search was conducted in electronic databases Medline, PubMed, and ScienceDirect, with search terms “microbiome and/or microbiota” and “radiotherapy (RT) and/or chemoradiation therapy (CRT)” and “cancer”, and the relevant literature were selected for use in this article. Results: Eight prospective cohort studies were selected for review with a total of 311 participants with a range of 15–134 participants within these studies. The selected studies were conducted in patients with gynaecological (n = 3), rectal (n = 2), or prostate cancers (n = 1), or patients with various types of malignancies (n = 2). Three studies reported that cancer patients had significantly lower alpha diversity compared with healthy controls. Seven studies found that lower alpha diversity and modulated gut microbiome were associated with GI toxicities during and after pelvic RT (n = 5) and CRT (n = 2), whereas one study found that beta diversity was related to a complete response following CRT. Two further studies reported that fatigue was associated with dysbiosis of the gut microbiome and low alpha diversity during and after RT, and with dysbiosis of the gut microbiome and diarrhoea, respectively. Conclusion: Gut microbiome profiles are associated with GI toxicities and have the potential to predict RT/CRT-induced toxicities and quality of life (QoL) in patients undergoing those treatments. Further robust randomized controlled trials (RCTs) are required to elucidate the effect of gut microbiome profiles on RT-related adverse effects and responses to RT.
- Published
- 2021
- Full Text
- View/download PDF
16. Oxidative stress in prostate cancer patients: A systematic review of case control studies
- Author
-
David S. Rosenthal, Neil Martine, Daniel S.J. Costa, George Hruby, Thomas Eade, Stephen Clarke, Aymen Elfiky, Michael Back, Byeongsang Oh, Gemma A. Figtree, and Stephanie H Lim
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Antioxidant ,Peroxidation ,Urology ,medicine.medical_treatment ,Review Article ,lcsh:RC870-923 ,urologic and male genital diseases ,medicine.disease_cause ,Pathogenesis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,Medicine ,chemistry.chemical_classification ,Reactive oxygen species ,business.industry ,Case-control study ,Cancer ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,030104 developmental biology ,chemistry ,Oxidative stress ,030220 oncology & carcinogenesis ,Immunology ,business - Abstract
© 2016 Background Prostate cancer (PCa) is the most common cancer in men in Western countries. In-vitro and in-vivo studies suggest that oxidative stress (OS) and antioxidants play a key role in the pathogenesis of chronic diseases including PCa, which is promoted by the production of reactive oxygen species and impaired antioxidant defense mechanisms. This study evaluates the association between OS and men with PCa. Methods A literature search was carried out on Medline, PubMed, and ScienceDirect databases, as well as manual searches from inception up to August 2015 using the keywords “Oxidative stress” or “Reactive oxygen species” or “Lipid peroxidation” AND “Prostate cancer.” All studies including data on the measurement of OS biomarkers in PCa were included. Results Twenty-three case control studies were retrieved with sample sizes ranging from 15 to 3,613 (6,439 participants in total). Markers of OS were significantly higher in patients with PCa compared with control groups in 21 studies. Two self-controlled case studies comparing OS between PCa cells and non-PCa cells in tissue biopsies found OS to be statistically higher in PCa cancer cells. Results on markers of antioxidant capacity (superoxide dismutase, catalase, glutathione, glutathione reductase, glutathione peroxidase, uric acid, lutein, lycopene, beta carotein, vitamin A, vitamin C, vitamin E, and total antioxidants) were not completely consistent in their association with PCa. Conclusions Upregulated OS profiles and impairment of antioxidant defense systems may play a role in men with PCa. To confirm these findings, robust clinical trials utilizing a personalized approach which monitors both OS and antioxidant markers during therapy are warranted.
- Published
- 2016
- Full Text
- View/download PDF
17. Epidermal inclusion cyst in the thyroid gland
- Author
-
Maria Naranjo Palacio, David S. Rosenthal, Qi Tao, Huijuan Liao, Salini Kunar, Luis F. Gonzalez-Mosquera, and Wondwossen Gebre
- Subjects
endocrine system ,Pathology ,medicine.medical_specialty ,integumentary system ,endocrine system diseases ,Epidermal Cyst ,medicine.diagnostic_test ,business.industry ,Thyroid ,Case Report ,Nodule (medicine) ,Dysphagia ,Epidermal Inclusion Cyst ,030218 nuclear medicine & medical imaging ,Surgical pathology ,03 medical and health sciences ,0302 clinical medicine ,Fine-needle aspiration ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cytology ,medicine ,medicine.symptom ,business - Abstract
Epidermal inclusion cysts (EIC) are common benign lesions of the skin, ovaries, and testicles. However, their occurrence in thyroid gland is rare. We reported a case in which a 57-year-old male patient with history of nontoxic uninodular goiter presented with dysphonia and dysphagia. The cytology of ultrasound guided fine needle aspiration of the thyroid nodule revealed epidermal cyst. Despite the benign presentation. The patient underwent lobectomy to relieve his clinical symptoms and the surgical pathology exam confirmed the diagnosis of benign thyroid cyst, consistent with EIC of the thyroid.
- Published
- 2020
- Full Text
- View/download PDF
18. Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions
- Author
-
Tish Knobf, Linda Larkey, Chi-hsiu D Weng, Michael R. Irwin, Penelope J. Klein, Peter Payne, Xinfeng Guo, Byeongsang Oh, Massimo Bonucci, Whanseok Choi, Chris Zaslawski, David S. Rosenthal, Michael Back, Carolyn Ee, Peiying Yang, Stephen Clarke, Mison Chun, Yulong Wei, Nick Pavlakis, Frances M. Boyle, Aymen Elfiky, Hanne-Doris Lang, Richard T. Lee, Albert Yeung, and Elisabet Stener-Victorin
- Subjects
certification ,media_common.quotation_subject ,education ,lcsh:Medicine ,Certification ,Tai Chi ,accreditation ,03 medical and health sciences ,0302 clinical medicine ,Promotion (rank) ,Complementary and Integrative Health ,Health care ,030212 general & internal medicine ,media_common ,Accreditation ,Medical education ,Government ,business.industry ,Qigong ,lcsh:R ,Guideline ,Concept Paper ,standards ,Patient Safety ,Integrative medicine ,business ,Psychology ,guideline ,human activities ,030217 neurology & neurosurgery ,Diversity (politics) - Abstract
Evidence of the health and wellbeing benefits of Tai Chi and Qigong (TQ) have emerged in the past two decades, but TQ is underutilized in modern health care in Western countries due to lack of promotion and the availability of professionally qualified TQ instructors. To date, there are no government regulations for TQ instructors or for training institutions in China and Western countries, even though TQ is considered to be a part of Traditional Chinese medicine that has the potential to manage many chronic diseases. Based on an integrative health care approach, the accreditation standard guideline initiative for TQ instructors and training institutions was developed in collaboration with health professionals, integrative medicine academics, Tai Chi and Qigong master instructors and consumers including public safety officers from several countries, such as Australia, Canada, China, Germany, Italy, Korea, Sweden and USA. In this paper, the rationale for organizing the Medical Tai Chi and Qigong Association (MTQA) is discussed and the accreditation standard guideline for TQ instructors and training institutions developed by the committee members of MTQA is presented. The MTQA acknowledges that the proposed guidelines are broad, so that the diversity of TQ instructors and training institutions can be integrated with recognition that these guidelines can be developed with further refinement. Additionally, these guidelines face challenges in understanding the complexity of TQ associated with different principles, philosophies and schools of thought. Nonetheless, these guidelines represent a necessary first step as primary resource to serve and guide health care professionals and consumers, as well as the TQ community.
- Published
- 2018
- Full Text
- View/download PDF
19. Contributors
- Author
-
Omar Abdel-Wahab, Janet L. Abrahm, Sharon Adams, Adeboye H. Adewoye, Carl Allen, Richard F. Ambinder, Claudio Anasetti, John Anastasi, Julia A. Anderson, Joseph H. Antin, Aśok C. Antony, David J. Araten, Philippe Armand, Gillian Armstrong, Scott A. Armstrong, Donald M. Arnold, Andrew S. Artz, Farrukh T. Awan, Trevor P. Baglin, Don M. Benson, Edward J. Benz, Nancy Berliner, Govind Bhagat, Nina Bhardwaj, Ravi Bhatia, Smita Bhatia, Mihir D. Bhatt, Vijaya Raj Bhatt, Menachem Bitan, Craig D. Blinderman, Catherine M. Bollard, Benjamin S. Braun, Malcolm K. Brenner, Gary M. Brittenham, Robert A. Brodsky, Myles Brown, Hal E. Broxmeyer, Kathleen Brummel-Ziedins, Andrew M. Brunner, Francis K. Buadi, Birgit Burkhardt, Melissa Burns, John C. Byrd, Paolo F. Caimi, Michael A. Caligiuri, Michelle Canavan, Alan B. Cantor, Manuel Carcao, Michael C. Carroll, Shannon A. Carty, Jorge J. Castillo, Anthony K.C. Chan, John Chapin, April Chiu, John P. Chute, David B. Clark, Thomas D. Coates, Christopher R. Cogle, Nathan T. Connell, Elizabeth Cooke, Sarah Cooley, Paolo Corradini, Mark A. Creager, Richard J. Creger, Caroline Cromwell, Mark A. Crowther, Melissa M. Cushing, Corey Cutler, Chi V. Dang, Nika N. Danial, Sandeep S. Dave, James A. DeCaprio, Mary C. Dinauer, Shira Dinner, Reyhan Diz-Küçükkaya, Roger Y. Dodd, Michele L. Donato, Kenneth Dorshkind, Gianpietro Dotti, Yigal Dror, Kieron Dunleavy, Christopher C. Dvorak, Benjamin L. Ebert, Michael J. Eck, John W. Eikelboom, Narendranath Epperla, William B. Ershler, William E. Evans, Stefan Faderl, James L.M. Ferrara, Alexandra Hult Filipovich, Martin Fischer, James C. Fredenburgh, Kenneth D. Friedman, Ephraim Fuchs, Stephen J. Fuller, David Gailani, Jacques Galipeau, Patrick G. Gallagher, Karthik A. Ganapathi, Lawrence B. Gardner, Adrian P. Gee, Stanton L. Gerson, Morie A. Gertz, Patricia J. Giardina, Christopher J. Gibson, Karin Golan, Todd R. Golub, Matthew J. Gonzales, Jason Gotlib, Stephen Gottschalk, Marianne A. Grant, Timothy A. Graubert, Xylina T. Gregg, John G. Gribben, Dawn M. Gross, Tanja A. Gruber, Joan Guitart, Sandeep Gurbuxani, Shiri Gur-Cohen, Alejandro Gutierrez, Mehdi Hamadani, Parameswaran N. Hari, John H. Hartwig, Suzanne R. Hayman, Catherine P.M. Hayward, Robert P. Hebbel, Helen E. Heslop, Christopher Hillis, Christopher D. Hillyer, Karin Ho, David M. Hockenbery, Ronald Hoffman, Kerstin E. Hogg, Shernan G. Holtan, Hans-Peter Horny, Yen-Michael S. Hsu, Zachary R. Hunter, James A. Huntington, Camelia Iancu-Rubin, Ali Iqbal, David E. Isenman, Sara J. Israels, Joseph E. Italiano, Elaine S. Jaffe, Iqbal H. Jaffer, Sundar Jagannath, Ulrich Jäger, Nitin Jain, Paula James, Sima Jeha, Michael B. Jordan, Cassandra D. Josephson, Moonjung Jung, Leo Kager, Taku Kambayashi, Jennifer A. Kanakry, Hagop M. Kantarjian, Jason Kaplan, Matthew S. Karafin, Aly Karsan, Randal J. Kaufman, Richard M. Kaufman, Frank G. Keller, Kara M. Kelly, Craig M. Kessler, Nigel S. Key, Alla Keyzner, Alexander G. Khandoga, Arati Khanna-Gupta, Eman Khatib-Massalha, Harvey G. Klein, Birgit Knoechel, Orit Kollet, Barbara A. Konkle, Dimitrios P. Kontoyiannis, John Koreth, Gary A. Koretzky, Dipak Kotecha, Marina Kremyanskaya, Anju Kumari, Timothy M. Kuzel, Ralf Küppers, Martha Q. Lacy, Elana Ladas, Wendy Landier, Kfir Lapid, Tsvee Lapidot, Peter J. Larson, Marcel Levi, Russell E. Lewis, Howard A. Liebman, David Lillicrap, Wendy Lim, Judith C. Lin, Robert Lindblad, Gregory Y.H. Lip, Jane A. Little, Jens G. Lohr, José A. López, Francis W. Luscinskas, Jaroslaw P. Maciejewski, Navneet S. Majhail, Olivier Manches, Robert J. Mandle, Kenneth G. Mann, Catherine S. Manno, Andrea N. Marcogliese, Guglielmo Mariani, Francesco M. Marincola, John Mascarenhas, Steffen Massberg, Rodger P. McEver, Emer McGrath, Matthew S. McKinney, Rohtesh S. Mehta, William C. Mentzer, Giampaolo Merlini, Reid Merryman, Marc Michel, Anna Rita Migliaccio, Jeffrey S. Miller, Martha P. Mims, Traci Heath Mondoro, Paul Moorehead, Luciana R. Muniz, Nikhil C. Munshi, Vesna Najfeld, Lalitha Nayak, Ishac Nazy, Anne T. Neff, Paul M. Ness, Luigi D. Notarangelo, Sarah H. O'Brien, Owen A. O'Connor, Martin O'Donnell, Amanda Olson, Stuart H. Orkin, Menaka Pai, Sung-Yun Pai, Michael Paidas, Sandhya R. Panch, Reena L. Pande, Thalia Papayannopoulou, Rahul Parikh, Effie W. Petersdorf, Shane E. Peterson, Stefania Pittaluga, Doris M. Ponce, Laura Popolo, Josef T. Prchal, Ching-Hon Pui, Pere Puigserver, Janusz Rak, Carlos A. Ramos, Jacob H. Rand, Margaret L. Rand, Dinesh S. Rao, Farhad Ravandi, David J. Rawlings, Pavan Reddy, Mark T. Reding, Andreas Reiter, Lawrence Rice, Matthew J. Riese, Arthur Kim Ritchey, David J. Roberts, Elizabeth Roman, Cliona M. Rooney, Steven T. Rosen, David S. Rosenthal, Marlies P. Rossmann, Antal Rot, Scott D. Rowley, Jeffrey E. Rubnitz, Natalia Rydz, Mohamed E. Salama, Steven Sauk, Yogen Saunthararajah, William Savage, David Scadden, Kristen G. Schaefer, Fred Schiffman, Robert Schneidewend, Stanley L. Schrier, Edward H. Schuchman, Bridget Fowler Scullion, Kathy J. Selvaggi, Keitaro Senoo, Montaser Shaheen, Beth H. Shaz, Samuel A. Shelburne, Elizabeth J. Shpall, Susan B. Shurin, Deborah Siegal, Leslie E. Silberstein, Lev Silberstein, Roy L. Silverstein, Steven R. Sloan, Franklin O. Smith, James W. Smith, Katy Smith, David P. Steensma, Martin H. Steinberg, Wendy Stock, Jill R. Storry, Susan L. Stramer, Ronald G. Strauss, David F. Stroncek, Justin Taylor, Swapna Thota, Steven P. Treon, Anil Tulpule, Roberto Ferro Valdes, Peter Valent, Suresh Vedantham, Gregory M. Vercellotti, Michael R. Verneris, Elliott P. Vichinsky, Ulrich H. von Andrian, Julie M. Vose, Andrew J. Wagner, Ena Wang, Jia-huai Wang, Theodore E. Warkentin, Melissa P. Wasserstein, Ann Webster, Daniel J. Weisdorf, Jeffrey I. Weitz, Connie M. Westhoff, Allison P. Wheeler, Page Widick, James S. Wiley, Basem M. William, David A. Williams, Wyndham H. Wilson, Joanne Wolfe, Lucia R. Wolgast, Deborah Wood, Jennifer Wu, Joachim Yahalom, Donald L. Yee, Anas Younes, Neal S. Young, and Michelle P. Zeller
- Published
- 2018
- Full Text
- View/download PDF
20. Integrative Therapies in Patients With Hematologic Diseases
- Author
-
Elana Ladas, David S. Rosenthal, and Ann Webster
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,Acupuncture ,In patient ,Mind-Body Medicine ,Intensive care medicine ,business - Published
- 2018
- Full Text
- View/download PDF
21. Acupuncture for Aromatase Inhibitor–Induced Arthralgia
- Author
-
Hwa-Seung Yoo, Kyeore Bae, Gillian Lamoury, Byeongsang Oh, David S. Rosenthal, and Frances M. Boyle
- Subjects
medicine.medical_specialty ,Side effect ,Electroacupuncture ,medicine.drug_class ,medicine.medical_treatment ,Acupuncture Therapy ,Breast Neoplasms ,law.invention ,Breast cancer ,Randomized controlled trial ,law ,medicine ,Acupuncture ,Humans ,Randomized Controlled Trials as Topic ,Aromatase inhibitor ,Aromatase Inhibitors ,business.industry ,medicine.disease ,Arthralgia ,Complementary and alternative medicine ,Oncology ,Sample size determination ,Joint pain ,Physical therapy ,Female ,medicine.symptom ,business - Abstract
Background. Aromatase inhibitors (AIs) are commonly used as adjunctive hormone treatment for early breast cancer patients. The major side effect of AIs is arthralgia, which affects adherence. Previous reviews suggested that acupuncture is effective in the management of cancer-related pain. The aim of this review is to evaluate the effects of acupuncture on arthralgia caused by AIs. Methods. This article examined randomized controlled trials (RCTs) measuring the effects of acupuncture on joint symptoms caused by AIs within 8 medical databases till May 2014. The quality of the articles was evaluated according to the Cochrane risk of bias (ROB) tool. Results. Four RCTs were identified in medical journals. Two studies were conducted with manual acupuncture and 2 studies were electroacupuncture. The range of sample size was between 32 and 67. One RCT showed significant improvement in the acupuncture group compared with the sham control group and another RCT showed a statistical difference between the electroacupuncture and waitlist group. The other 2 studies showed no statistical differences between control and acupuncture groups. Two studies conducted blood analysis to elucidate the mechanism of efficacy of acupuncture for arthralgia. The 2 positive studies had a lower ROB and 2 studies had a high ROB. Conclusions. The systematic review suggests that acupuncture has potential benefits to improve arthralgia caused by AIs. However, further trials of adequate sample size, appropriate control group, and longer follow-up are necessary to investigate the efficacy of acupuncture in AI-induced arthralgia.
- Published
- 2015
- Full Text
- View/download PDF
22. Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
- Author
-
David S. Rosenthal, Byeongsang Oh, Jihun Kim, and Weidong Lu
- Subjects
Article Subject ,Cell growth ,Fucoidan ,medicine.drug_class ,business.industry ,medicine.medical_treatment ,lcsh:Other systems of medicine ,Pharmacology ,lcsh:RZ201-999 ,Lapatinib ,Tyrosine-kinase inhibitor ,In vitro ,Targeted therapy ,chemistry.chemical_compound ,Complementary and alternative medicine ,chemistry ,In vivo ,Cancer cell ,medicine ,skin and connective tissue diseases ,business ,Research Article ,medicine.drug - Abstract
Background. Despite a number ofin vitroandin vivostudies reporting the efficacy of fucoidan in treating various cancers, few studies have measured the efficacy of dietary fucoidan (DF) in combination with cancer drugs. Thus, we examined the sensitivity of DF in combination with the EGFR/ERBB2-targeting reagent lapatinib on cancer cells.Method. We selected six EGFR/ERBB2-amplified cancer cell lines (OE19, NCI-N87, OE33, ESO26, MKN7, and BT474) as anin vitromodel and tested their sensitivity to DF alone and to DF in combination with the well-known EGFR/ERBB2-targeting reagent lapatinib.Result. Overall, in drug independent sensitivity test, DF alone did not significantly inhibit the growth of EGFR/ERBB2-amplified cancer cellsin vitro. When DF was given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action of lapatinib in ESO26, NCI-N87, and OE19.Conclusion. This study suggests that DF has the potential to increase or decrease the effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.
- Published
- 2014
- Full Text
- View/download PDF
23. Effects of Qigong on Depression: A Systemic Review
- Author
-
Albert Yeung, Byeongsang Oh, David S. Rosenthal, Sun Mi Choi, and Aya Inamori
- Subjects
medicine.medical_specialty ,business.industry ,Clinical study design ,Physical exercise ,lcsh:Other systems of medicine ,Review Article ,PsycINFO ,lcsh:RZ201-999 ,law.invention ,Clinical trial ,Mood ,Complementary and alternative medicine ,Randomized controlled trial ,law ,Physical therapy ,medicine ,business ,human activities ,Depression (differential diagnoses) ,Management of depression - Abstract
Physical exercises and relaxation have been found to be beneficial for depression. However, there is little evidence on the use of Qigong, a mind-body practice integrating gentle exercise and relaxation, in the management of depression. The aim of this paper is to evaluate the effects of Qigong on depression. The paper examined clinical trials measuring the effect of Qigong on depression within six large-scale medical research databases (PubMed, Medline, ProQuest, Science Direct, EMBASE, and PsycInfo) till October 2011. Key words “Qigong,” “depression,” and “mood” were used. Ten studies were identified as original randomized controlled trial (RCT) studies investigating the effect of Qigong on depression as primary (n=2) or secondary outcome (n=8). Four studies reported positive results of the Qigong treatment on depression; two reported that Qigong effect on depression was as effective as physical exercise. One study reported that Qigong was comparable to a conventional rehabilitation program, but the remaining three studies found no benefits of Qigong on depression. While the evidence suggests the potential effects of Qigong in the treatment of depression, the review of the literature shows inconclusive results. Further research using rigorous study designs is necessary to investigate the effectiveness of Qigong in depression.
- Published
- 2013
- Full Text
- View/download PDF
24. Thyroid and Parathyroid Diseases
- Author
-
Michele N Minuto, Alice L Tang, Richard B Cannon, Michael C Singer, Kenneth H Hupart, Bruce Curtiss Gilbert, Ramon E Figueroa, David J. Terris, Paul W Biddinger, Sara L Richer, Jennifer Yu, Paolo Miccoli, Ralph P Tufano, Chung-Yau Lo, Brendan C. Stack, Anatoly P Romanchishen, Salem I Noureldine, Dipti Kamani, Carlos M Isales, Gerard M Doherty, Radu Mihai, James A Lee, Russell B Smith, R. Michael Tuttle, Sarah C. Oltmann, Steven R Bomeli, Katrina Chaung, Robert C Smallridge, Wendy B Bollag, Mira Milas, Jason P Hunt, Jennifer Leonard, Sara Ahmadi, Herbert Chen, Brian Lang, David S Rosenthal, Gregory W Randolph, Daniel Kwon, Megan R. Haymart, Jaime L Wiebel, Rahul Modi, Rosemarie Metzger, Gabriele Materazzi, David L Steward, Jacqueline Jonklaas, Alfred Simental, Latha V Pasupuleti, Susan J Hsiao, Galimat Khaidakova, William S. Duke, Luc G.T. Morris, Maisie L Shindo, Brian R Untch, Geoffrey B Thompson, Yuri E Nikiforov, Emanuela Varaldo, Victor J Bernet, and Jeffrey F Moley
- Subjects
medicine.medical_specialty ,Renal hyperparathyroidism ,business.industry ,General surgery ,education ,Thyroid ,medicine.disease ,Patient care ,Robotic thyroidectomy ,medicine.anatomical_structure ,Otorhinolaryngology ,Current practice ,medicine ,Patient evaluation ,business ,Thyroid cancer - Abstract
Praise for the previous edition: "At once a textbook, a surgical atlas, and a source of current practice guidelines...This is a high-quality, thorough and insightful resource that provides accessible and essential information...recommend[ed]." -- Doody's Review Thyroid and Parathyroid Diseases, Second Edition, has been revised and updated to reflect recent advances in the medical and surgical management of thyroid and parathyroid diseases. This new edition serves as both a comprehensive guide to patient evaluation as well as an atlas of advanced surgical techniques for managing patients needing operative intervention. Separate chapters are devoted to minimally invasive techniques and remote access/robotic thyroidectomy techniques, both of which have enjoyed increased application throughout the world. New in the second edition: * A section on state-of-the-art, evidence-based management of challenging parathyroid conditions such as multiple endocrine neoplasia and renal hyperparathyroidism * A more detailed discussion of thyroid cancer evaluation and staging * A new chapter dedicated to parathyroid cancer * Nearly 200 additional full-color illustrations This new edition is a valuable resource for all surgeons, endocrinologists, and residents seeking to expand their knowledge of thyroid and parathyroid diseases, as well as seasoned clinicians who want to improve patient care and incorporate the latest surgical advancements into their practice.
- Published
- 2016
- Full Text
- View/download PDF
25. Acupuncture for dysphagia after chemoradiation in head and neck cancer: Rationale and design of a randomized, sham-controlled trial
- Author
-
Julie E. Buring, Peter M. Wayne, Roger B. Davis, Weidong Lu, Roy B. Tishler, Robert I. Haddad, Laura A. Goguen, Hailun Li, Marshall R. Posner, and David S. Rosenthal
- Subjects
Adult ,Research design ,medicine.medical_specialty ,Patient Dropouts ,Adolescent ,Acupuncture Therapy ,Pilot Projects ,Article ,law.invention ,Young Adult ,Clinical Protocols ,Double-Blind Method ,Randomized controlled trial ,Swallowing ,law ,otorhinolaryngologic diseases ,Acupuncture ,Humans ,Medicine ,Pharmacology (medical) ,Young adult ,Aged ,Aged, 80 and over ,business.industry ,Patient Selection ,Head and neck cancer ,Chemoradiotherapy ,General Medicine ,Middle Aged ,medicine.disease ,Dysphagia ,Surgery ,Treatment Outcome ,Head and Neck Neoplasms ,Research Design ,Carcinoma, Squamous Cell ,Quality of Life ,Physical therapy ,Feasibility Studies ,medicine.symptom ,Deglutition Disorders ,business - Abstract
Dysphagia is a common side effect following chemoradiation therapy (CRT) in head and neck cancer (HNC) patients. Current dysphagia management includes swallowing therapy and dilation procedures, but these treatments have limitations. While acupuncture has been reported to positively impact swallowing function and quality of life (QOL) in patients with dysphagia, current evidence is inconclusive.In an ongoing trial, 42 squamous cell carcinoma HNC patients, who are receiving platinum-based CRT with curative intent, are being recruited from a comprehensive cancer center. They are randomized to 12 sessions of either active acupuncture or to sham acupuncture during and following CRT over a 24-week period. Blinded research staff assesses outcomes at baseline, 20 weeks post-CRT (end of acupuncture), and 12 months after baseline (6-month follow-up). The primary outcome is change in M.D. Anderson Dysphagia Inventory score from baseline to 12 months. Secondary outcomes include QOL measures pertaining to HNC patients. In addition, a subset of study patients are tested for salivary flow rates and cytokines, including plasma transforming growth factor-β1 and interleukin 6 (n=10 per arm), to preliminarily explore the biological mechanisms of acupuncture for dysphagia.This paper addresses unique challenges related to study design in nonpharmacological, sham-controlled acupuncture trials including development of evidence-based credible verum and sham treatment protocols, blinding, and assuring fidelity of treatment. Results of this study will inform the feasibility of conducting a large scale trial and will provide preliminary evidence regarding the value of acupuncture for dysphagia in HNC patients.
- Published
- 2012
- Full Text
- View/download PDF
26. The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia
- Author
-
David S. Rosenthal, Barbara Mullan, Stephen Clarke, Byeongsang Oh, Philip Beale, Nick Pavlakis, and Phyllis Butow
- Subjects
medicine.medical_specialty ,animal structures ,Palliative care ,business.industry ,Alternative medicine ,MEDLINE ,Cancer ,General Medicine ,medicine.disease ,Oncology ,Family medicine ,medicine ,University teaching ,Young adult ,Adverse effect ,business ,Survival rate - Abstract
Aim: The use of complementary and alternative medicine (CAM) by cancer patients is growing. However, few studies have examined the perceived benefits and adverse effects resulting from the use of CAM by cancer patients. The aim of this study was to evaluate CAM use by cancer patients and to explore their perceptions of the benefit, safety and efficacy of CAM in general. Methods: Oncologists from three university teaching hospitals screened patients for eligibility. Eligible patients (N = 1323) were mailed a letter of invitation with a questionnaire between January and May 2008. Results: Overall 381 questionnaires were returned, showing that 65% of cancer patients used at least one form of CAM. Patients considered taking biological CAM before, during and after chemotherapy. Up to 90% of CAM users believed that CAM provided potential health benefits and less than 3% reported adverse effects experienced from the use of CAM. Most respondents (80%) believed CAM can provide health benefits even when efficacy has not been proven. Most patients (90%) believed that doctors should consider learning about CAM to provide appropriate advice to their cancer patients, and most (83%) indicated they would be happier to accept CAM if it was offered by the hospital. Conclusion: A substantial portion of Australian cancer patients use CAM. Given the limited data on efficacy and safety for most CAM, it may be reasonable to offer CAM within the hospital environment so its use can be monitored and patients can receive more evidence-based care.
- Published
- 2010
- Full Text
- View/download PDF
27. Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial
- Author
-
L. Lam, Nick Pavlakis, Byeongsang Oh, Philip Beale, David S. Rosenthal, Phyllis Butow, Barbara Mullan, Emily Kothe, and Stephen Clarke
- Subjects
Adult ,Male ,medicine.medical_specialty ,mood ,Health Status ,Affect (psychology) ,Breathing Exercises ,law.invention ,Quality of life ,Randomized controlled trial ,law ,Neoplasms ,Surveys and Questionnaires ,Internal medicine ,Outcome Assessment, Health Care ,cancer ,Humans ,Medicine ,Adverse effect ,Aged ,Aged, 80 and over ,Inflammation ,biology ,business.industry ,C-reactive protein ,Case-control study ,Cancer ,Original Articles ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Affect ,C-Reactive Protein ,Mood ,Oncology ,Case-Control Studies ,Quality of Life ,Physical therapy ,biology.protein ,fatigue ,Female ,business - Abstract
Background: Substantial numbers of cancer patients use complementary medicine therapies, even without a supportive evidence base. This study aimed to evaluate in a randomized controlled trial, the use of Medical Qigong (MQ) compared with usual care to improve the quality of life (QOL) of cancer patients. Patients and methods: One hundred and sixty-two patients with a range of cancers were recruited. QOL and fatigue were measured by Functional Assessment of Cancer Therapy-General and Functional Assessment of Cancer Therapy-Fatigue, respectively, and mood status by Profile of Mood State. The inflammatory marker serum C-reactive protein (CRP) was monitored serially. Results: Regression analysis indicated that the MQ group significantly improved overall QOL (t(144) = -5.761, P < 0.001), fatigue (t(153) = -5.621, P < 0.001), mood disturbance (t(122) =2.346, P = 0.021) and inflammation (CRP) (t(99) = 2.042, P < 0.044) compared with usual care after controlling for baseline variables. Conclusions: This study indicates that MQ can improve cancer patients' overall QOL and mood status and reduce specific side-effects of treatment. It may also produce physical benefits in the long term through reduced inflammation.
- Published
- 2010
- Full Text
- View/download PDF
28. Integrative Tumor Board: A Case Report and Discussion From Dana-Farber Cancer Institute
- Author
-
Maria B. Mathay, Elizabeth Dean-Clower, Weidong Lu, Anne Doherty-Gilman, Stacy Kennedy, David S. Rosenthal, Mary Jane Ott, and Carolyn Hayes
- Subjects
Adult ,Complementary Therapies ,medicine.medical_specialty ,Diet therapy ,medicine.medical_treatment ,Acupuncture Therapy ,Breast Neoplasms ,Anxiety ,Article ,Breast cancer ,Drug Therapy ,Humans ,Medicine ,Family history ,Mastectomy ,Massage ,Integrative Medicine ,Radiotherapy ,Integrative Oncology ,BRCA1 Protein ,business.industry ,Yoga ,General surgery ,Academies and Institutes ,Cancer ,Prophylactic Mastectomy ,medicine.disease ,Complementary and alternative medicine ,Oncology ,Quality of Life ,Physical therapy ,Female ,Integrative medicine ,business ,Stress, Psychological ,Diet Therapy - Abstract
A 34-year-old woman carrying a BRCA1 gene and a significant family history was diagnosed with T1c, N1 breast cancer. The tumor was estrogen receptor, progesterone receptor, and HER-2/Neu negative.The patient received dose-dense chemotherapy with Adriamycin and Cytoxan followed by Taxol, and left breast irradiation. Later, a bilateral S-GAP flap reconstruction with right prophylactic mastectomy and left mastectomy were performed. During her treatment, the patient had an integrative medicine consultation and was seen by a team of health care providers specializing in integrative therapies, including integrative nutrition, therapeutic massage, acupuncture, and yoga. Each modality contributed unique benefit in her care that led to a satisfactory outcome for the patient.A detailed discussion regarding her care from each modality is presented.The case elucidates the need for integrative approaches for cancer patients in a conventional medical setting.
- Published
- 2009
- Full Text
- View/download PDF
29. Acupuncture for Chemotherapy-Induced Neutropenia in Patients with Gynecologic Malignancies: A Pilot Randomized, Sham-Controlled Clinical Trial
- Author
-
Peter M. Wayne, Julie E. Buring, Elizabeth Dean-Clower, Annekathryn Goodman, Andrew Rosulek, Hang Lee, Roger B. Davis, Anne Doherty-Gilman, David S. Rosenthal, C. Gibson, Ursula A. Matulonis, Weidong Lu, and Richard T. Penson
- Subjects
Adult ,medicine.medical_specialty ,Neutropenia ,medicine.medical_treatment ,Acupuncture Therapy ,Antineoplastic Agents ,Pilot Projects ,law.invention ,Leukocyte Count ,Randomized controlled trial ,law ,Internal medicine ,Acupuncture ,medicine ,Humans ,Ovarian Neoplasms ,Chemotherapy ,Myelosuppressive Chemotherapy ,business.industry ,Cancer ,Original Articles ,Middle Aged ,medicine.disease ,Surgery ,Clinical trial ,Complementary and alternative medicine ,Absolute neutrophil count ,Female ,business - Abstract
The objective of this study was to investigate the effect of acupuncture administered during myelosuppressive chemotherapy on white blood cell (WBC) count and absolute neutrophil count (ANC) in patients with ovarian cancer.This study is a pilot, randomized, sham-controlled clinical trial. Patients received active acupuncture versus sham acupuncture while undergoing chemotherapy. A standardized acupuncture protocol was employed with manual and electrostimulation. The frequency of treatment was 2-3 times per week for a total of 10 sessions, starting 1 week before the second cycle of chemotherapy.The setting was two outpatient academic centers for patients with cancer.Twenty-one (21) newly diagnosed and recurrent ovarian cancer patients were the subjects.WBC count, ANC, and plasma granulocyte colony-stimulating factor (G-CSF ) were assessed weekly.The median leukocyte value in the acupuncture arm at the first day of the third cycle of chemotherapy was significantly higher than in the control arm after adjusting for baseline value (8600 cells/microL, range: 4800-12,000 versus 4400 cell/microL, range: 2300-10,000) (p = 0.046). The incidence of grade 2-4 leukopenia was less in the acupuncture arm than in the sham arm (30% versus 90%; p = 0.02). However, the median leukocyte nadir, neutrophil nadir, and recovering ANC were all higher but not statistically significantly different (p = 0.116-0.16), after adjusting for baseline differences. There were no statistically significant differences in plasma G-CSF between the two groups.We observed clinically relevant trends of higher WBC values during one cycle of chemotherapy in patients with ovarian cancer, which suggests a potential myeloprotective effect of acupuncture. A larger trial is warranted to more definitively determine the efficacy of acupuncture on clinically important outcomes of chemotherapy-induced neutropenia.
- Published
- 2009
- Full Text
- View/download PDF
30. The Value of Acupuncture in Cancer Care
- Author
-
David S. Rosenthal, Elizabeth Dean-Clower, Anne Doherty-Gilman, and Weidong Lu
- Subjects
medicine.medical_specialty ,Palliative care ,Gastrointestinal Diseases ,Acupuncture Therapy ,Alternative medicine ,MEDLINE ,Pain ,Antineoplastic Agents ,Anxiety ,Cancer Care Facilities ,Article ,Neoplasms ,Sleep Initiation and Maintenance Disorders ,Care plan ,Acupuncture ,Animals ,Humans ,Pain Management ,Medicine ,Acupuncture Analgesia ,Intensive care medicine ,Fatigue ,Randomized Controlled Trials as Topic ,Brain Mapping ,Clinical Trials as Topic ,Depression ,business.industry ,Palliative Care ,Cancer ,Hematology ,medicine.disease ,Clinical research ,Oncology ,Physical therapy ,business - Abstract
Clinical research on acupuncture in cancer care is a new and challenging field in oncology. The results of clinical research will continue to provide clinically relevant answers for patients and oncologists. The evidence currently available has suggested that acupuncture is a safe and effective therapy to manage cancer and treatment related symptoms, while giving patients the ability to actively participate in their own care plan. The article explains the potential benefits of acupuncture and describes the difficulties in studying its effectiveness.
- Published
- 2008
- Full Text
- View/download PDF
31. Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial
- Author
-
Roger B. Davis, Marshall R. Posner, Eric A. Macklin, Weidong Lu, Tyler C Haddad, Elaine Burke, Jochen H. Lorch, Peter M. Wayne, Laura A. Goguen, Julie E. Buring, David S. Rosenthal, Roy B. Tishler, Robert I. Haddad, and Hailun Li
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Acupuncture Therapy ,Pilot Projects ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Quality of life ,law ,medicine ,Acupuncture ,Humans ,Stage (cooking) ,030223 otorhinolaryngology ,MD Anderson Dysphagia Inventory ,Aged ,business.industry ,Head and neck cancer ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Dysphagia ,Head and Neck Cancer ,Clinical trial ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Physical therapy ,Quality of Life ,Female ,medicine.symptom ,business ,Deglutition Disorders - Abstract
INTRODUCTION Dysphagia is common in head and neck cancer patients after concurrent chemoradiation therapy (CRT). This study evaluated the feasibility of conducting a randomized sham-controlled trial and collected preliminary data on safety and efficacy of acupuncture. PATIENTS AND METHODS Head and neck cancer (HNC) patients with stage III-IV squamous cell carcinoma were randomized to 12 sessions of either active acupuncture (AA) or sham acupuncture (SA) during and following CRT. Patients were blinded to treatment assignment. Swallowing-related quality of life (QOL) was assessed using the MD Anderson Dysphagia Inventory (MDADI) total and subscale scores. RESULTS Multiple aspects of trial feasibility were confirmed. Forty-two of 196 patients screened (21%) were enrolled and randomized to receive AA (n = 21) or SA (n = 21); 79% completed at least 10 of 12 planned acupuncture sessions; 81% completed the study follow-ups. The majority of patients reported uncertainty regarding their treatment assignment, with no difference between the AA and SA groups. Audits confirmed both AA and SA treatments were delivered with high fidelity. No serious acupuncture-related side effects were observed. MDADI total scores significantly improved from baseline to 12 months post-CRT in both groups (AA: +7.9; SA +13.9; p = .044, p < .001). Similar patterns were observed for the MDADI global subscale (AA: +25.0; SA +22.7; p = .001, p = .002). Intent-to-treat analyses suggested no difference between the treatment groups (p = .17, p = .76 for MDADI total and global scores, respectively). CONCLUSION A sham-controlled randomized trial evaluating acupuncture in dysphagia-related QOL in HNC found the procedure to be feasible and safe. Further investigation is required to evaluate efficacy. IMPLICATIONS FOR PRACTICE Dysphagia or swallowing difficulty is an important and common condition after concurrent chemoradiation therapy in head and neck cancer patients. In addition to current available supportive care, acupuncture may offer potential for treating dysphagia. This study demonstrated that both active acupuncture and sham acupuncture are safe and were associated with improved dysphagia-related quality of life from baseline to 12 months after concurrent chemoradiation therapy. This study was not designed to inform underlying specific versus nonspecific effects. Future larger-scale pragmatic clinical trials evaluating the effectiveness of acupuncture versus standard of care are warranted, and further mechanistic research is needed to understand how active versus purportedly sham acupuncture procedures affect dysphagia-related symptoms.
- Published
- 2015
32. The Evaluation of a Mind/Body Intervention to Reduce Psychological Distress and Perceived Stress in College Students
- Author
-
David S. Rosenthal, Gloria R. Deckro, Kelli M. Ballinger, Michael A. Hoyt, Patricia Myers, Marilyn Wilcher, Beth Greenberg, Jeffrey Dusek, and Herbert Benson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Stress management ,Adolescent ,Universities ,medicine.medical_treatment ,education ,Perceived Stress Scale ,medicine ,Humans ,Prospective Studies ,Students ,Psychiatry ,Relaxation (psychology) ,Mind-Body Therapies ,Cognitive restructuring ,Public Health, Environmental and Occupational Health ,Middle Aged ,United States ,Cognitive behavioral therapy ,Distress ,Treatment Outcome ,Cognitive therapy ,Anxiety ,Female ,medicine.symptom ,Psychology ,Stress, Psychological ,Clinical psychology - Abstract
The authors examined the effect of a 6-week mind/body intervention on college students' psychological distress, anxiety, and perception of stress. One hundred twenty-eight students were randomly assigned to an experimental group (n = 63) or a waitlist control group (n = 65). The experimental group received 6 90-minute group-training sessions in the relaxation response and cognitive behavioral skills. The Symptom Checklist-90-Revised, Spielberger State-Trait Anxiety Inventory, and the Perceived Stress Scale were used to assess the students' psychological state before and after the intervention. Ninety students (70% of the initial sample) completed the postassessment measure. Significantly greater reductions in psychological distress, state anxiety, and perceived stress were found in the experimental group. This brief mind/body training may be useful as a preventive intervention for college students, according to the authors, who called for further research to determine whether the observed treatment effect can be sustained over a longer period of time.
- Published
- 2002
- Full Text
- View/download PDF
33. Abstract PD4-01: Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial
- Author
-
Laura Shockro, Nu Lin, K Stecker, Anita Giobbie-Hurder, Keelin O'Connor, Rachel A. Freedman, Weidong Lu, David S. Rosenthal, AH Partridge, Rachel L. Yung, and Jennifer A. Ligibel
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,030205 complementary & alternative medicine ,law.invention ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Breast cancer ,Peripheral neuropathy ,Oncology ,Chemotherapy-induced peripheral neuropathy ,Quality of life ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,Internal medicine ,Acupuncture ,medicine ,Physical therapy ,business - Abstract
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the major dose-limiting side effects in breast cancer patients, with up to 97% of patients receiving an adjuvant taxane experiencing this symptom in the months and years after breast cancer treatment. CIPN often leads to loss of physical function; difficulties in activities of daily living and decreased of quality of life (QOL). Few effective interventions have been developed to alleviate CIPN in this patient population. We conducted a pilot randomized controlled trial to assess the feasibility, safety and preliminary effect of an acupuncture intervention on CIPN in breast cancer survivors. METHODS: Patients with stage I-III breast cancer who were experiencing CIPN after the completion of a taxane-containing adjuvant chemotherapy regimen were enrolled and randomized 1:1 to immediate participation in an acupuncture intervention or to a delayed intervention control group. Participants randomized to the acupuncture arm received 18 sessions of a standardized acupuncture protocol over 8 weeks while the control group received a lower-dose acupuncture protocol consisting of 9 acupuncture sessions over 8 weeks, after the initial 8-week control period. Measures including the Patient Neurotoxicity Questionnaire (PNQ), Functional Assessment of Cancer Therapy Neurotoxicity subscale (FACT-NTX), and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20) were collected at baseline and at 8 weeks after enrollment. RESULTS: A total of 40 patients were enrolled; 20 were randomized to the immediate acupuncture group and 20 to control. All enrolled patients were female, median age was 54, median time between enrollment and completion of chemotherapy was 14.3 months, and 72.5% of participants were White. Thirty-two patients (84%) completed at least 80% of the required sessions. No serious acupuncture-related side effects were observed. Participants randomized to the acupuncture arm experienced improvements in the PNQ sensory score (p=0.02), FACT-NTX summary score (p=0.002) and EORTC QLQ-CIPN20 score (p=0.006), respectively equivalent to 40%, 36% and 53% improvement in CIPN symptoms, as compared to controls. MeasurementsTime pointsAcupunctureUsual CareP-valueNMeanSDMeanSDPNQ summary sensory score (0-4)Baseline202.50.82.50.90.97Changes at 8 week15-1.00.9-0.30.60.02FACT-NTX summary score (0-44)Baseline2025.08.422.19.40.40Changes at 8 week159.09.21.25.40.002EORTC QLQ-CIPN20 sensory score (0-100)Baseline2044.919.945.022.30.93Changes at 8 week15-23.818.1-5.16.40.006 CONCLUSIONS: Women with CIPN after adjuvant taxane therapy for early breast cancer experienced a significant and clinically meaningful improvement in neuropathy symptoms as a result of an 8-week acupuncture protocol. Given the prevalence of taxane-induced neuropathy in women treated for early breast cancer, acupuncture could significantly improve QOL and functional status of thousands of women treated for breast cancer every year. Larger studies are needed to confirm these findings and evaluate the impact of acupuncture on functional measures in women with CIPN. Citation Format: Lu W, Giobbie-Hurder A, Freedman R, Yung R, Lin N, Partridge A, Shockro L, Stecker K, O'Connor KA, Rosenthal DS, Ligibel JA. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD4-01.
- Published
- 2017
- Full Text
- View/download PDF
34. Integrative Medicine in Oncology
- Author
-
Weidong Lu and David S. Rosenthal
- Subjects
medicine.medical_specialty ,business.industry ,Family medicine ,medicine ,Integrative medicine ,business - Published
- 2014
- Full Text
- View/download PDF
35. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial
- Author
-
Weidong Lu, Hang Lee, Peter M. Wayne, Richard T. Penson, David S. Rosenthal, Julie Dunn, Elizabeth Dean-Clower, Roger B. Davis, Julie E. Buring, Ursula A. Matulonis, Anne Doherty-Gilman, and Annekathryn Goodman
- Subjects
Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cancer ,Original Articles ,Neutropenia ,medicine.disease ,Carboplatin ,law.invention ,chemistry.chemical_compound ,Complementary and alternative medicine ,chemistry ,Quality of life ,Randomized controlled trial ,law ,Acupuncture ,Physical therapy ,Medicine ,business ,Ovarian cancer - Abstract
Within a pilot trial regarding chemotherapy-induced neutropenia, the secondary aim of the main study was explored. This involved measuring the effects-as shown on two key measurement scales reflecting quality of life (QoL)-of verum versus sham acupuncture on patients with ovarian cancer during chemotherapy.The aim of this substudy was to determine the feasibility of determining the effects of verum acupuncture versus sham acupuncture on QoL in patients with ovarian cancer during chemotherapy.This was a randomized, sham-controlled trial.The trial was conducted at two cancer centers.Patients with ovarian cancer (The participants were given either active or sham acupuncture 1 week prior to cycle 2 of chemotherapy. There were ten sessions of acupuncture, with manual and electro-stimulation over a 4-week period.The European Organization for Research and Treatment of Cancer-Quality-of-Life Questionnaire-Core 30 Item (EORTC-QLQ-C30) and the Quality of Life Questionnaire-Ovarian Cancer Module-28 Item (QLQ-OV28) were administered to the patients at baseline and at the end of their acupuncture sessions.Of the original 21, 15 patients (71%) completed the study, and 93% of them completed the questionnaires. The EORTC-QLQ-C30 subscores were improved in the acupuncture arm, including the mean scores of social function (SF), pain, and insomnia (It appears feasible to conduct a randomized sham-controlled acupuncture trial measuring QoL for patients with ovarian cancer who are undergoing chemotherapy. Acupuncture may have a role in improving QoL during chemotherapy.
- Published
- 2014
36. Effects of Qigong on Quality of Life, Fatigue, Stress, Neuropathy, and Sexual Function in Women with Metastatic Breast Cancer: A Feasibility Study
- Author
-
Esther L Davis, Philip Beale, Byeongsang Oh, Costa Dsj, Phyllis Butow, Nick Pavlakis, Frances M. Boyle, Choi Sm, David S. Rosenthal, Susan J. Clark, Lee Ms, and David R. Bell
- Subjects
medicine.medical_specialty ,business.industry ,Perceived Stress Scale ,Cancer ,medicine.disease ,Omics ,Metastatic breast cancer ,Peripheral neuropathy ,Quality of life ,Physical therapy ,Medicine ,business ,Sexual function ,Adverse effect - Abstract
Background: Women with metastatic breast cancer (MBC) suffer from psychological and physiological symptoms and side effects of therapy. When the treatment is non-curative, quality of life (QOL) is a major issue. This study aimed to examine the feasibility, safety, and effects of Medical Qigong (MQ: integration of gentle exercise and meditation) in improving QOL in women with MBC. Method: Women with MBC were randomized to a MQ group (n=14) or meditation control group (n=13). QOL, fatigue, stress, neuropathy symptoms and sexual function were measured by the Functional Assessment of Cancer Therapy - Breast (FACT-B), Functional Assessment of Cancer Therapy-fatigue (FACT-F), Perceived Stress Scale (PSS), neurotoxicity subscale of the FACT/GOG-NTX, and Sexual Functioning Questionnaire (SFQ) subscales at pre-intervention and weeks 5 and 10. Results: No serious adverse events were reported during or after MQ intervention. Sixty three percent of participants completed the study (MQ intervention (n=9) and meditation control (n=8)). There were no significant differences in overall QOL (p= 0.84), fatigue (p=0.71), perceived stress level (p=0.52), sexual satisfaction (p=0.55), sexual activities (p=0.95) and sexual relationship (p=0.79) between the groups, although difference in neuropathic symptoms (p=0.014) were significant. Conclusions: A MQ trial in women with MBC is feasible and safe. MQ may have the potential to relieve symptoms experienced by women with MBC and prevent deterioration of neuropathy. A larger study with adequate power to confirm these results and detect clinically relevant effects is needed.
- Published
- 2014
- Full Text
- View/download PDF
37. COMPLEMENTARY & ALTERNATIVE METHODS
- Author
-
Terri Ades and David S. Rosenthal
- Subjects
Alternative methods ,Oncology ,business.industry ,Management science ,Medicine ,Hematology ,business - Published
- 2001
- Full Text
- View/download PDF
38. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U. S
- Author
-
David S. Rosenthal, Curtis Mettlin, Herman R. Menck, and Gerald P. Murphy
- Subjects
Gynecology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Prostatectomy ,Incidence (epidemiology) ,medicine.medical_treatment ,Mortality rate ,Brachytherapy ,Cancer ,medicine.disease ,Radiation therapy ,Oncology ,Internal medicine ,medicine ,Carcinoma ,Adenocarcinoma ,business - Abstract
Background Prostate carcinoma incidence has been declining since 1992 after a period of marked increase. Recent data from the National Cancer Data Base (NCDB) were examined to assess changes in prostate carcinoma patient characteristics and disease and treatment patterns coincidental to this decline. The NCDB is a program of the American College of Surgeons Commission on Cancer and the American Cancer Society that collects timely data from institutions representing every level of cancer care. Methods Data from 1114 hospitals regarding 103,979 patients diagnosed with prostate carcinoma in 1992 and from 1144 hospitals regarding 72,337 patients diagnosed in 1995 were studied. Patient and disease characteristics studied included age, race, American Joint Committee on Cancer stage, and tumor histologic grade. Trends in treatment and variations in treatment by region also were examined. Results The average age at diagnosis declined by 2 years over the period studied and the proportion of patients identified as African-American increased from 8.8% to 11.8%. The proportion of patients diagnosed with localized disease and the proportion of tumors of moderately differentiated histologic grade increased. The overall proportion of patients treated by radical prostatectomy increased and the use of external beam radiation treatment decreased. Substantial regional variation in treatment patterns was observed. The Pacific and Mountain state regions of the U. S. had the highest proportions of patients treated by radical prostatectomy although increases were occurring in other regions. Use of external beam radiation treatment was highest in the Northeast and Southeast states and was declining in the majority of regions. Use of brachytherapy radiation treatment by implantation of radioactive seeds was infrequent but increasing. Conclusions Comparison of the basic characteristics of prostate carcinoma data from 1992 and 1995 shows that patients are being diagnosed at younger ages and earlier stages, the proportion of African-Americans has increased, and more patients are being treated for cure. Regional differences in patterns of care persist but may be moderating. The annual prostate carcinoma death rate in the U.S. has declined an average of 1% per year since 1990.
- Published
- 1998
- Full Text
- View/download PDF
39. Collaborative approaches to purchasing and managing oncology services for a prepaid population
- Author
-
Mary N. Hennings, Marc N. Pollack, Debra A. Connolly, Maureen M. Lynch, and David S. Rosenthal
- Subjects
Service (business) ,Oncology ,Cancer Research ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Population ,Context (language use) ,Purchasing ,Nursing ,Internal medicine ,Health care ,medicine ,Managed care ,education ,business ,Reimbursement ,Health policy - Abstract
BACKGROUND. Change created by managed care plans is producing tensions among oncology care providers, health plans, patients, and employers. Managed care plans, which now are dominant, are engendering concern among some patients and providers because those plans limit provider choice and reimbursement, as well as inject themselves in clinical decision-making. Collaborative approaches to purchasing and managing oncology service for a prepaid population should help reduce these tensions. METHODS. This article provides a case history of how Harvard University Health Services, a managed care delivery and insurance program serving the university collaborates with contracted oncology providers. The described approach defines mutually beneficial payment and shared responsibility for care in the context of patient centered values. As a part of this collaborative effort, liberal experimental treatment coverage is offered. RESULTS. Patient care is improved because the flow of clinical information among caregivers is improved. When communication is more open, nurse case managers who work for the managed care plan also can arrange for covered services in a more expeditious manner. CONCLUSIONS. Collaboration among health plans, oncologists, and other health care providers to provide patients with high quality, cost-effective care on a fully informed basis is challenging, but not impossible. The key is to define common ground and commitment to the needs of patients among health plans and providers.
- Published
- 1998
- Full Text
- View/download PDF
40. Acupuncture for Cancer Pain and Related Symptoms
- Author
-
David S. Rosenthal and Weidong Lu
- Subjects
Male ,medicine.medical_specialty ,Vomiting ,Electroacupuncture ,Nausea ,medicine.medical_treatment ,Pain medicine ,Acupuncture Therapy ,Antineoplastic Agents ,Guidelines as Topic ,Article ,Neoplasms ,medicine ,Acupuncture ,Humans ,Pain Management ,business.industry ,Cancer ,General Medicine ,medicine.disease ,United States ,Pain, Intractable ,Analgesics, Opioid ,Treatment Outcome ,Anesthesiology and Pain Medicine ,Joint pain ,Physical therapy ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Cancer pain ,Postoperative nausea and vomiting - Abstract
Cancer pain is one of most prevalent symptoms in patients with cancer. Acupuncture and related techniques have been suggested for the management of cancer pain. The National Comprehensive Cancer Network (NCCN®) guidelines for adult cancer pain recommends acupuncture, as one of integrative interventions, in conjunction with pharmacologic intervention as needed. This review presents the latest available evidence regarding the use of acupuncture for cancer pain. It also provides “actionable” acupuncture protocols for specific cancer pain conditions and related symptoms in order to provide more clinically relevant solutions for clinicians and cancer patients with pain. These conditions include postoperative cancer pain, postoperative nausea and vomiting, postsurgical gastroparesis syndrome, opioid-induced constipation, opioid-induced pruritus, chemotherapy-induced neuropathy, aromatase inhibitor-associated joint pain, and neck dissection-related pain and dysfunction.
- Published
- 2013
- Full Text
- View/download PDF
41. A University Outbreak of Gastroenteritis Due to a Small Round-Structured Virus: Application of Molecular Diagnostics to Identify the Etiologic Agent and Patterns of Transmission
- Author
-
Patricia E. Kludt, Charles D. Humphrey, Ermias D. Belay, Stephan S. Monroe, Howard E. Gary, Daniel M. Hamlin, Jacqueline S. Noel, David S. Rosenthal, Paul E. Kilgore, Tamie Ando, Jonathan Freeman, and Roger I. Glass
- Subjects
medicine.medical_specialty ,Restaurants ,Universities ,Biology ,medicine.disease_cause ,Virus ,Disease Outbreaks ,Microbiology ,law.invention ,law ,Epidemiology ,medicine ,Humans ,Immunology and Allergy ,Feces ,Outbreak ,Molecular diagnostics ,Virology ,Gastroenteritis ,Norwalk virus ,Infectious Diseases ,Transmission (mechanics) ,Massachusetts ,Case-Control Studies ,Norovirus ,Viral disease ,Caliciviridae - Abstract
An epidemiologic investigation of a gastroenteritis outbreak in December 1994 indicated that salad consumption during lunch was linked with illness on 2 days (5 December : odds ratio [OR] = 3.1, 95% confidence interval [CI] = 2.0-5.0 ; 6 December : OR = 3.1, 95% CI = 1.9-4.9). Single stool or vomitus specimens from ill students and staff (case-patients) were examined for bacterial and viral pathogens. Small round-structured viruses (SRSVs) were detected by electron microscopy in stool specimens from 9 of 19 case-patients and in vomitus specimens from 3 of 5 case-patients. By reverse transcription-polymerase chain reaction (RT-PCR), the SRSVs were shown to be a G-2/P2-B type strain. The nucleotide sequences of RT-PCR products from vomitus and stool specimens of ill students were identical to stool specimens from the ill salad chef. These findings suggest that a single SRSV strain was the etiologic agent in the outbreak that was possibly transmitted to students through consumption of contaminated salad. Epidemiologic investigation in conjunction with molecular diagnostics may enable early identification of sources of infection and improve outbreak control.
- Published
- 1996
- Full Text
- View/download PDF
42. Effects of Qigong Therapy on Alleviating Symptoms in Cancer Patients: An Overview of Systematic Reviews
- Author
-
Byeongsang Oh, Myeong Soo Lee, David S. Rosenthal, and Edzard Ernst
- Subjects
Selection bias ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Symptomatic treatment ,MEDLINE ,Alternative medicine ,Cancer ,Cochrane Library ,medicine.disease ,Systematic review ,Quality of life ,parasitic diseases ,medicine ,Physical therapy ,business ,media_common - Abstract
Owing to the limitations and side effects of conventional cancer treatment, especially in relation to quality of life, patients are increasingly utilizing complementary and alternative medicine to supplement health-related outcomes. However, evidence for the safety and efficacy of such treatments is lacking. Qigong is often used to improve the symptoms of cancer patients, although scientific evidence is unclear. The aim of this chapter was to critically evaluate all systematic reviews (SRs) of Qigong for the symptomatic treatment of cancer. We searched 11 electronic databases including MEDLINE, Embase, AMED, the Cochrane Library, six Korean Medical Databases, and a Chinese Database and our departmental files without restrictions on time or language. The search terms involved the following MeSH terms: “Qigong” AND “systematic review OR meta-analysis” AND “cancer”. The methodological quality of all SRs was evaluated using the Overview Quality Assessment Questionnaire. Of 26 potentially relevant publications, five met our inclusion criteria. Three SRs evaluated the effects of both internal and external Qigong. One SR evaluated the effect of internal Qigong, and another evaluated external Qigong. The quality of the SRs was mixed but two SRs had minor flaws only. All SRs noted that the quality of most primary studies was poor. The conclusions of the five SRs were inconsistent. The poor quality SRs tended to draw positive conclusions, while the higher quality SRs failed to do so. More than 50% of the primary studies included in the SRs were not randomized and thus open to selection bias, which may be the primary reason for the inconsistency in the conclusions of the SRs. Overall, no clearly positive conclusions were identified. It follows that Qigong as a symptomatic treatment for cancer is currently not supported by sound evidence.
- Published
- 2012
- Full Text
- View/download PDF
43. Integrative medicine and cancer care
- Author
-
David S. Rosenthal and Anne Doherty-Gilman
- Subjects
medicine.medical_specialty ,animal structures ,Health (social science) ,business.industry ,Health Policy ,media_common.quotation_subject ,Alternative medicine ,Evidence-based medicine ,Bioethics ,Mind–body interventions ,Issues, ethics and legal aspects ,Family medicine ,Acupuncture ,Medicine ,Integrative medicine ,Meditation ,business ,Medical ethics ,media_common - Abstract
Integrative medicine combines the best of both conventional and evidence-based CAM therapies for treatment, wellness, and prevention. 61 percent of cancer survivors have used CAM.
- Published
- 2012
44. Myelodysplasia
- Author
-
Martha Wadleigh, David S. Rosenthal, and Richard M. Stone
- Published
- 2012
- Full Text
- View/download PDF
45. Subclinical Thyrotoxicosis Associated with Lithium Therapy
- Author
-
Monika Goyal, David S Rosenthal, and Kenneth H Hupart
- Published
- 2011
- Full Text
- View/download PDF
46. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy
- Author
-
David S. Rosenthal, B A Barbara Silver, George Canellos, C. Norman Coleman, Peter Mauch, Lawrence N. Shulman, Minoru Uematsu, Nancy J. Tarbell, and Howard Weinstein
- Subjects
Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cancer ,Combination chemotherapy ,Retrospective cohort study ,Disease ,medicine.disease ,Wide field ,Lymphoma ,Surgery ,Radiation therapy ,Oncology ,Medicine ,business - Abstract
Background. Patients with Hodgkin disease who have relapses after initial chemotherapy (CT) appear to have a poor prognosis, especially if the duration of the first complete remission (CR) was short. The authors performed a retrospective analysis of patients with Hodgkin disease whose relapse after combination CT was limited to nodal sites; their aim was to study the prognosis of this selected subgroup of patients. Methods. In 28 patients with Hodgkin disease who had relapses in nodal sites after combination CT alone, the disease was restaged carefully to rule out simultaneous extranodal recurrences. Then the patients were treated with wide-field, high-dose radiation therapy (RT) with or without additional CT with curative intent between 1971 and 1987 at the Joint Center for Radiation Therapy. Fourteen patients were in first relapse and were treated with combination CT followed by RT. The remaining 14 patients (8 who were in first relapse and 6 who were in second relapse) were treated with RT alone. RT techniques were similar to those recommended for early-stage disease. Results. The 7-year actuarial freedom from relapse and survival rates for the patients retreated with CT and RT were 93% and 85%, respectively, as compared with 36% and 36% for patients retreated with RT alone. There was a significant difference for freedom from relapse (P = 0.002) and survival (P = 0.03), favoring patients retreated with both CT and RT. Conclusions. This retrospective study demonstrates that RT combined with second-line CT can result in a high percentage of durable remissions in patients who have relapses primarily in nodal sites after original treatment with combination CT alone. These durable remissions are seen even in patients who have only a brief CR after initial CT. Cancer 1993; 72:207–12.
- Published
- 1993
- Full Text
- View/download PDF
47. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial
- Author
-
Linda Larkey, Phyllis Butow, David S. Rosenthal, Byeongsang Oh, Barbara Mullan, Philip Beale, Nick Pavlakis, Janette L. Vardy, Myeong Soo Lee, and Stephen Clarke
- Subjects
Adult ,Male ,medicine.medical_specialty ,Inflammation ,Disease ,Breathing Exercises ,law.invention ,Perceived cognitive abilities ,Quality of life ,Randomized controlled trial ,law ,Internal medicine ,Neoplasms ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Cancer ,Cognition ,Middle Aged ,medicine.disease ,C-Reactive Protein ,Oncology ,Physical therapy ,Quality of Life ,Biomarker (medicine) ,Female ,medicine.symptom ,business ,Cognition Disorders ,Biomarkers - Abstract
Cancer patients often experience diminished cognitive function (CF) and quality of life (QOL) due to the side effects of treatment and the disease symptoms. This study evaluates the effects of medical Qigong (MQ; combination of gentle exercise and meditation) on CF, QOL, and inflammation in cancer patients. Eighty-one cancer patients recruited between October 2007 and May 2008 were randomly assigned to two groups: a control group (n = 44) who received the usual health care and an intervention group (n = 37) who participated in a 10-week MQ program. Self-reported CF was measured by the European Organization for Research and Treatment of Cancer (EORTC-CF) and the Functional Assessment of Cancer Therapy—Cognitive (FACT-Cog). The Functional Assessment of Cancer Therapy—General (FACT-G) was used to measure QOL. C-reactive protein (CRP) was assessed as a biomarker of inflammation. The MQ group self-reported significantly improved CF (mean difference (MD) = 7.78, t 51 = −2.532, p = 0.014) in the EORTC-CF and all the FACT-Cog subscales [perceived cognitive impairment (MD = 4.70, t 43 = −2.254, p = 0.029), impact of perceived cognitive impairment on QOL (MD = 1.64, t 45 = −2.377, p = 0.024), and perceived cognitive abilities (MD = 3.61, t 45 = −2.229, p = 0.031)] compared to controls. The MQ group also reported significantly improved QOL (MD = 12.66, t 45 = −5.715, p
- Published
- 2010
48. Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report
- Author
-
Marshall R. Posner, Robert I. Haddad, Weidong Lu, Peter M. Wayne, and David S. Rosenthal
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Acupuncture Therapy ,Article ,Enteral Nutrition ,Swallowing ,medicine ,Acupuncture ,Carcinoma ,Combined Modality Therapy ,Humans ,Intubation, Gastrointestinal ,Aged ,Gastrostomy ,business.industry ,Head and neck cancer ,Middle Aged ,medicine.disease ,Dysphagia ,Surgery ,Deglutition ,Radiation therapy ,Complementary and alternative medicine ,Oncology ,Head and Neck Neoplasms ,Carcinoma, Squamous Cell ,Female ,medicine.symptom ,business ,Deglutition Disorders - Abstract
Background: Dysphagia is a common side effect following chemoradiation therapy (CRT) in patients with head and neck cancer (HNC). Methods: In this retrospective case series, 10 patients with HNC were treated with acupuncture for radiation-induced dysphagia and xerostomia. All patients were diagnosed with stage III/IV squamous cell carcinoma. In all, 7 of 10 patients were percutaneous endoscopic gastrostomy (PEG) tube dependent when they began acupuncture. Manual acupuncture and electroacupuncture were used once a week. Results: A total of 9 of 10 patients reported various degrees of subjective improvement in swallowing functions, xerostomia, pain, and fatigue levels. Overall, 6 (86%) of 7 PEG tube-dependent patients had their feeding tubes removed after acupuncture, with a median duration of 114 days (range 49 to 368 days) post CRT. One typical case is described in detail. Conclusions: A relatively short PEG tube duration and reduced symptom severity following CRT were observed in these patients. Formal clinical trials are required to determine the causality of the observations.
- Published
- 2010
49. Clinical Aspects of Chronic Myeloproliferative Diseases
- Author
-
David S. Rosenthal
- Subjects
medicine.medical_specialty ,Myeloproliferative Disorders ,Myeloid ,Thrombocytosis ,business.industry ,General Medicine ,Disease ,medicine.disease ,Dermatology ,Therapeutic modalities ,Diagnosis, Differential ,Chronic myeloproliferative disorders ,Polycythemia vera ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Metaplasia ,Chronic Disease ,Immunology ,medicine ,Humans ,medicine.symptom ,Myelofibrosis ,business - Abstract
The nonleukemic chronic myeloproliferative disorders, polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis, are clonal disorders with similar but distinct clinical and laboratory findings. This review will discuss the diagnostic criteria for each disease, the variable clinical picture, and the therapeutic modalities, actual and theoretical.
- Published
- 1992
- Full Text
- View/download PDF
50. Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer
- Author
-
Elizabeth Dean-Clower, Judith Manola, William B. Stason, Clair J. Beard, Herbert Benson, Susan DeCristofaro, Jeffery A. Dusek, David S. Rosenthal, Ann Webster, Anne Doherty-Gilman, and Qian Wang
- Subjects
Complementary Therapies ,Male ,Cancer Research ,Therapeutic touch ,medicine.medical_specialty ,Randomization ,medicine.medical_treatment ,Therapeutic Touch ,Reiki ,Relaxation Therapy ,Reiki Therapy ,law.invention ,Prostate cancer ,Randomized controlled trial ,law ,medicine ,Humans ,Aged ,Psychological Tests ,business.industry ,Prostatic Neoplasms ,medicine.disease ,Radiation therapy ,Clinical trial ,Mental Health ,Treatment Outcome ,Oncology ,Physical therapy ,Patient Compliance ,business - Abstract
BACKGROUND. This pilot randomized controlled trial (RCT) examined the clinical effects of 2 complementary (CAM) therapies, relaxation response therapy (RRT) and Reiki therapy, in men being treated with external beam radiotherapy (EBRx) for prostate cancer. METHODS. Study participants were randomly assigned to weekly RRT, Reiki therapy twice weekly, or wait-list control. Well-validated instruments measured anxiety (STAI), depression (CES-D), and quality of life in cancer patients (FACT-G) at randomization and 3 subsequent time points. RESULTS. Fifty-four men were randomized, and 16 of 18 (89%) of RRT and 15 of 18 (83%) of Reiki patients completed the intervention protocol. No statistically significant difference was found between the RRT, Reiki, and control groups on total scores for the STAI, CES-D, or FACT-G instruments at any time point. However, at the end of the intervention, significant improvement was found on the emotional well-being subscale of the FACT-G quality of life scale in the RRT group compared with the Reiki and control groups (P ¼ .01). In participants who were classified as ‘‘anxious’’ at baseline, statistically significant improvement occurred in the RRT group (P ¼ .02), and a positive trend was found in the Reiki group (P ¼ .10). CONCLUSIONS. This pilot study documented the feasibility of conducting a RCT of CAM therapies in men undergoing EBRx for prostate cancer. Relaxation response therapy improved emotional well being and eased anxiety in participants. Reiki therapy also had a positive effect in anxious patients. A larger study to verify and better define the benefits of these therapies in men with prostate cancer is warranted. Cancer 2010;00:000–000. V C 2010 American Cancer Society .
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.